SCYX - SCYNEXIS Inc Stock Price, Fair Value and News

2.72USD+0.31 (+12.86%)Delayed as of 17 May 2024, 12:59 pm ET

Market Summary

USD2.72+0.31

Delayedas of 17 May 2024, 12:59 pm

12.86%

SCYX Stock Price

View Fullscreen

SCYX RSI Chart

SCYX Valuation

Market Cap

91.0M

Price/Earnings (Trailing)

0.9

Price/Sales (Trailing)

0.65

EV/EBITDA

0.53

Price/Free Cashflow

1.21

SCYX Price/Sales (Trailing)

SCYX Profitability

Operating Margin

89.50%

EBT Margin

72.80%

Return on Equity

136.74%

Return on Assets

85.69%

Free Cashflow Yield

82.46%

SCYX Fundamentals

SCYX Revenue

Revenue (TTM)

140.1M

Rev. Growth (Yr)

282.01%

Rev. Growth (Qtr)

229.38%

SCYX Earnings

Earnings (TTM)

101.3M

Earnings Growth (Yr)

101.21%

Earnings Growth (Qtr)

102.1%

Breaking Down SCYX Revenue

52 Week Range

1.733.87

(Low)(High)

Last 7 days

27.1%

Last 30 days

69.5%

Last 90 days

39.0%

Trailing 12 Months

-16.4%

How does SCYX drawdown profile look like?

SCYX Financial Health

Current Ratio

3.72

SCYX Investor Care

Shares Dilution (1Y)

3.46%

Diluted EPS (TTM)

2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	38.9M	72.6M	106.4M	140.1M
2022	1.8M	3.1M	4.2M	5.1M
2021	5.5M	8.0M	10.6M	13.2M
2020	673.0K	476.0K	311.0K	2.9M
2019	394.5K	532.0K	669.5K	807.0K
2018	483.5K	672.5K	823.5K	257.0K
2017	221.0K	264.0K	325.0K	385.5K
2016	220.0K	195.0K	179.0K	180.0K
2015	1.3M	1.3M	1.3M	257.0K
2014	0	0	0	1.3M
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SCYNEXIS Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	sukenick scott	sold (taxes)	-24,741	1.63	-15,179	chief legal officer
Jan 26, 2024	macleod ivor	acquired	-	-	143,675	chief financial officer
Jan 26, 2024	angulo gonzalez david	acquired	-	-	290,590	chief executive officer
Jan 26, 2024	sukenick scott	acquired	-	-	143,675	chief legal officer
Jun 15, 2023	gilman steven c	acquired	-	-	10,000	-
Jun 15, 2023	macdonald guy	acquired	-	-	10,000	-
Jun 15, 2023	hanham ann	acquired	-	-	10,000	-
Jun 15, 2023	hastings david c	acquired	-	-	10,000	-
Jun 15, 2023	anido armando	acquired	-	-	10,000	-
Jun 15, 2023	tinmouth brian philippe	acquired	-	-	10,000	-

Which funds bought or sold SCYX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-80,659	156,011	-%
May 15, 2024	MORGAN STANLEY	added	64.36	2,922	37,933	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	145	327,507	855,298	-%
May 15, 2024	Avidity Partners Management LP	unchanged	-	-1,101,030	2,129,630	0.07%
May 15, 2024	Squarepoint Ops LLC	added	405	153,806	219,734	-%
May 15, 2024	Man Group plc	sold off	-100	-275,287	-	-%
May 15, 2024	CORSAIR CAPITAL MANAGEMENT, L.P.	new	-	69,672	69,672	0.02%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-19.31	-53,985	61,337	-%
May 15, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	reduced	-50.00	-6,688,770	3,288,460	0.36%
May 15, 2024	Royal Bank of Canada	sold off	-100	-37,000	-	-%

Are Funds Buying or Selling SCYX?

Are funds buying SCYX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SCYX

No. of Funds

Unveiling SCYNEXIS Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	stonepine capital management, llc	3.6%	1,355,186	SC 13G/A
Feb 13, 2024	caxton corp	0%	0	SC 13G/A
Feb 13, 2024	avidity partners management lp	9.9%	3,968,816	SC 13G/A
Jan 18, 2024	federated hermes, inc.	19.99%	8,094,700	SC 13G/A
Nov 29, 2023	kingdon capital management, l.l.c.	6.02%	2,237,048	SC 13G/A
Jun 09, 2023	stonepine capital management, llc	7.6%	2,777,877	SC 13G
Apr 13, 2023	kingdon capital management, l.l.c.	5.1%	1,697,048	SC 13G
Apr 03, 2023	hirschman orin	3.5%	1,159,346	SC 13G/A
Feb 15, 2023	hirschman orin	5.3%	1,932,046	SC 13G/A
Feb 14, 2023	armistice capital, llc	4.72%	1,618,411	SC 13G/A

Recent SEC filings of SCYNEXIS Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 16, 2024	4	Insider Trading
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to SCYNEXIS Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	371.3B	85.6B	6.80%	-2.97%	9.65	4.33	5.68%	202.39%
MRK	331.6B	61.4B	4.69%	14.08%	143.8	5.4	6.11%	-82.30%
AMGN	168.9B	29.5B	18.50%	39.89%	44.87	5.72	12.76%	-52.47%
PFE	163.9B	57.8B	12.61%	-21.28%	130.78	2.84	76.51%	-86.81%
GILD	84.6B	27.4B	0.85%	-13.87%	174.55	3.08	1.51%	-91.32%
TEVA	18.5B	16.0B	24.52%	100.49%	-37.33	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	2.99%	-21.03%	9.53	2.4	54.01%	364.56%
PRGO	4.1B	4.6B	0.47%	-8.40%	-532.89	0.9	-0.06%	94.55%
BHC	2.6B	9.0B	-19.11%	-5.35%	-5.7	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	4.47%	-0.56%	13.51	3.09	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	16.39%	-11.62%	-4.68	2.22	24.65%	80.36%
TXMD	24.2M	1.3M	10.53%	-49.88%	-3.27	18.6	-98.14%	-104.71%
ACRX	19.7M	89.6M	13.73%	58.80%	-1.39	0.19	287.27%	-129.41%
AGRX	2.6M	21.5M	2.56%	-90.89%	-0.34	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

SCYNEXIS Inc News

Latest updates

SCYNEXIS Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	5,797,000	1,760,000	131,454,000	66,485,750	1,517,500	1,557,000	1,323,000	700,000	597,000	516,000	-	12,050,000	6,027,500	5,000	36,000	147,000	123,000	170,000	233,000	281,000
Operating Expenses	-62.3%	10,881,000	28,861,500	11,859,000	14,940,000	11,812,000	24,004,500	23,358,000	23,061,000	20,425,000	22,893,000	19,957,000	17,508,000	13,644,000	15,335,000	11,511,000	11,826,000	12,479,000	14,107,500	11,756,000	11,253,000	11,925,000
S&GA Expenses	2.1%	3,669,000	3,592,000	5,014,000	7,474,000	4,840,000	15,902,500	16,739,000	15,786,000	14,591,000	15,036,000	15,411,000	12,774,000	6,696,000	5,177,500	3,481,000	3,357,000	2,613,000	3,147,500	2,480,000	2,779,000	2,241,000
R&D Expenses	-31.9%	7,212,000	10,586,500	6,466,000	7,040,000	6,835,000	7,906,000	6,430,000	7,131,000	5,735,000	7,690,000	4,401,000	4,734,000	6,948,000	10,157,500	8,030,000	8,469,000	9,866,000	10,960,000	9,276,000	8,474,000	9,684,000
EBITDA Margin	47.1%	0.74	0.51	0.73	0.70	-2.19	-12.10	-18.43	-15.47	-21.24	-2.50	-4.46	-5.78	-	-	-	-	-	-	-	-	-
Interest Expenses	-7.7%	205,000	222,000	212,000	1,249,000	1,447,000	1,529,000	1,379,000	1,231,000	1,059,000	982,000	1,019,000	445,000	214,000	322,000	330,000	319,000	210,000	209,500	203,000	209,000	367,000
Income Taxes	284.8%	531,000	138,000	-	-	-	-	-	-	-4,700,000	-	-50,000	-4,138,000	1,100,000	-4,000	-	-3,144,000	-	-	-	-	-
Earnings Before Taxes	104.8%	942,000	-19,427,000	-1,757,000	122,260,000	-33,876,000	-14,429,000	-29,584,000	-13,345,000	-10,151,000	-29,243,000	-655,000	-2,480,000	-3,576,000	-42,682,000	909,000	-9,525,000	-7,002,000	-14,458,000	-7,941,000	-8,403,000	-
EBT Margin	51.8%	0.73	0.48	0.68	0.61	-2.35	-13.24	-19.71	-17.03	-23.46	-2.73	-4.66	-5.96	-	-	-	-	-	-	-	-	-
Net Income	102.1%	411,000	-19,586,000	-1,757,000	122,260,000	-33,876,000	-14,429,000	-29,584,000	-13,345,000	-5,451,000	-29,243,000	-605,000	1,658,000	-4,676,000	-42,711,000	909,000	-6,381,000	-7,002,000	-14,458,000	-7,941,000	-8,403,000	-22,908,000
Net Income Margin	51.1%	0.72	0.48	0.68	0.61	-2.35	-12.32	-18.58	-15.51	-18.56	-2.50	-4.37	-5.59	-	-	-	-	-	-	-	-	-
Free Cashflow	48.2%	-4,007,000	-7,735,000	12,419,000	74,398,000	-18,923,000	-22,806,000	-22,508,000	-18,581,000	-15,988,000	-25,520,000	-16,586,000	-11,695,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.9%	118	128	149	155	70.00	88.00	112	136	112	120	110	121	100	103	37.00	45.00	42.00	57.00	34.00	41.00	45.00
Current Assets	-0.4%	102	102	129	146	60.00	79.00	104	126	102	109	104	116	95.00	98.00	32.00	41.00	37.00	52.00	29.00	36.00	40.00
Cash Equivalents	5.8%	36.00	34.00	44.00	58.00	27.00	46.00	69.00	119	95.00	105	100	113	92.00	93.00	30.00	34.00	21.00	42.00	12.00	19.00	13.00
Inventory	-	-	-	13.00	10.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	0.00	-	-	-	-	-	-	-	-	-
Net PPE	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-20.4%	44.00	55.00	57.00	62.00	100	85.00	95.00	90.00	73.00	79.00	72.00	89.00	74.00	80.00	27.00	39.00	35.00	44.00	28.00	31.00	34.00
Current Liabilities	67.8%	27.00	16.00	17.00	16.00	46.00	18.00	14.00	16.00	13.00	14.00	13.00	20.00	25.00	26.00	8.00	7.00	7.00	11.00	8.00	7.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	1.6%	74.00	73.00	92.00	93.00	-29.91	3.00	17.00	45.00	39.00	41.00	38.00	32.00	26.00	23.00	10.00	6.00	6.00	13.00	6.00	10.00	11.00
Retained Earnings	0.1%	-354	-355	-335	-333	-456	-422	-407	-378	-364	-359	-330	-329	-331	-326	-283	-284	-278	-271	-256	-249	-240
Additional Paid-In Capital	0.2%	429	428	428	427	426	425	425	424	404	401	368	362	357	349	293	291	285	284	263	259	252
Shares Outstanding	1.5%	38.00	37.00	37.00	37.00	33.00	33.00	41.00	38.00	32.00	29.00	27.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	109,140,501	-	-	-	60.00	-	-	-	169	-	-	-	78.00	-	-	-	70.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	48.2%	-4,007	-7,735	12,419	74,398	-18,923	-22,806	-22,508	-18,581	-15,988	-25,520	-16,586	-11,695	-759	-16,572	-9,869	-8,856	-14,057	-13,458	-10,402	-7,758	-6,501
Share Based Compensation	26.6%	705	557	632	728	707	454	1,210	1,100	922	581	588	500	398	1,000	399	411	410	441	449	446	492
Cashflow From Investing	353.4%	5,454	-2,152	-26,341	-6,384	-	-	-27,380	-	-9.00	-583	-338	-51.00	-200	-	3,571	10,665	-7,762	10,044	-421	10,020	6,597
Cashflow From Financing	88.9%	-15.00	-135	34.00	-36,642	22.00	-	-183	42,062	6,723	30,478	4,533	32,180	-71.00	80,119	1,771	11,959	152	33,715	3,237	3,938	1,415

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SCYX Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 1,373	$ 1,130
Operating expenses:
Cost of product revenues	0	137
Research and development	7,212	6,835
Selling, general and administrative	3,669	4,840
Total operating expenses	10,881	11,812
Loss from operations	(9,508)	(10,682)
Other (income) expense:
Amortization of debt issuance costs and discount	401	255
Interest income	(1,280)	(587)
Interest expense	205	1,447
Warrant liabilities fair value adjustment	(9,608)	21,673
Derivative liabilities fair value adjustment	(168)	406
Total other (income) expense	(10,450)	23,194
Income (loss) before taxes	942	(33,876)
Income tax expense	(531)	0
Net income (loss)	$ 411	$ (33,876)
Net income (loss) per share attributable to common stockholders - basic
Net income (loss) per share - basic	$ 0.01	$ (0.71)
Net income (loss) per share attributable to common stockholders - diluted
Net income (loss) per share - diluted	$ 0.01	$ (0.71)
Weighted average common shares outstanding – basic and diluted
Basic	48,245,559	47,757,246
Diluted	48,565,051	47,757,246
Product Revenue, Net
Revenue:
Total revenue	$ 0	$ 1,130
License Agreement Revenue
Revenue:
Total revenue	$ 1,373	$ 0

SCYX Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,482	$ 34,050
Short-term investments	44,762	40,312
Prepaid expenses and other current assets	1,583	5,548
License agreement receivable	0	2,463
License agreement contract asset	19,466	19,363
Restricted cash	380	380
Total current assets	101,673	102,116
Investments	13,943	23,594
Deferred offering costs	175	175
Restricted cash	163	163
Operating lease right-of-use asset (See Note 7)	2,300	2,364
Total assets	118,254	128,412
Current liabilities:
Accounts payable	8,918	7,149
Accrued expenses	4,601	7,495
Deferred revenue, current portion	1,083	1,189
Operating lease liability, current portion (See Note 7)	356	340
Warrant liabilities	0	130
Convertible debt and derivative liability (See Note 6)	12,391	0
Total current liabilities	27,349	16,303
Deferred revenue	2,111	2,727
Warrant liabilities	12,202	21,680
Convertible debt and derivative liability (See Note 6)	0	12,159
Operating lease liability (See Note 7)	2,487	2,581
Total liabilities	44,149	55,450
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 37,779,796 and 37,207,799 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	41	40
Additional paid-in capital	428,900	428,169
Accumulated deficit	(354,836)	(355,247)
Total stockholders' equity	74,105	72,962
Total liabilities and stockholders’ equity	$ 118,254	$ 128,412

About SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

CEO	Mr. David Gonzalez Angulo M.D.
WEBSITE	scynexis.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	36

SCYNEXIS Inc Frequently Asked Questions

What is the ticker symbol for SCYNEXIS Inc? What does SCYX stand for in stocks?

SCYX is the stock ticker symbol of SCYNEXIS Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SCYNEXIS Inc (SCYX)?

As of Thu May 16 2024, market cap of SCYNEXIS Inc is 91.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers. The fair value of SCYNEXIS Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SCYNEXIS Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SCYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SCYNEXIS Inc a good stock to buy?

The fair value guage provides a quick view whether SCYX is over valued or under valued. Whether SCYNEXIS Inc is cheap or expensive depends on the assumptions which impact SCYNEXIS Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCYX.

What is SCYNEXIS Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SCYX's PE ratio (Price to Earnings) is 0.9 and Price to Sales (PS) ratio is 0.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SCYNEXIS Inc's stock?

In the past 10 years, SCYNEXIS Inc has provided -0.304 (multiply by 100 for percentage) rate of return.